Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Issued Key U.S. Patent for High-Pressure Flow-Through Microfluidic Sample Preparation Device

Pressure BioSciences (OTCQB: PBIO) this morning announced the award of a key new U.S. patent, entitled ”Flow-through High Hydrostatic Pressure Microfluidic Sample Preparation Device and Related Methods Therefor.” The company’s creation provides a path for integration of automated ”Hands-Free” sample prep workflows utilizing PBIO’s patented high-pressure platform technologies. The newly issued patent brings Pressure BioSciences’ Intellectual Property (”IP”) to a total of 21 issued patents. “This long-anticipated patent is a very important development for the Company on multiple fronts, and the timing of its issuance could not be better. This invention covers key elements of our plans for developing automated, ”hands-free” sample handling for the next generation of our high-pressure sample preparation platform technologies. This invention also enables a unique capability for maintaining high pressure in a flow-through format (rather than current batch processing), which we expect will facilitate the development of new, automated continuous process monitoring tools applicable to diverse segments of the life sciences industry. Finally, we believe this novel flow-through concept offers critical enablement for future system design strategies for epitope characterization, an emerging area in development and production of biotherapeutics that could revolutionize personalized therapy for numerous medical conditions, including autoimmune diseases and a variety of rare medical disorders,” Pressure BioSciences Vice President of Research and Development Dr. Alexander Lazarev stated in the news release.

To view the full press release, visit

About Pressure BioSciences Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in MissionIRNewsBreaks, Pressure BioSciences Inc. PBIO. Bookmark the permalink.

Comments are closed.